Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683824 · ClinicalTrials.gov registry record · Early Phase 1
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT02683824: Completed Early Phase 1 study, sponsored by Stanford University.
NCT02683824 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683824, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the use of integrin alpha-v-beta \[18F\]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. \[18F\]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DIAGNOSTIC_TEST Computed Tomography
- DIAGNOSTIC_TEST PET/MRI scan
- DRUG [18F]FP-R01-MG-F2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-01-12 |
| Est. Completion | 2022-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683824
The ClinicalTrials.gov registry entry for NCT02683824 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02683824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683824 about?
NCT02683824 is a clinical study titled "Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers". This pilot clinical trial studies the use of integrin alpha-v-beta \[18F\]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Int...
What is the current status of trial NCT02683824?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2016-01-12. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT02683824?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Computed Tomography (DIAGNOSTIC_TEST), PET/MRI scan (DIAGNOSTIC_TEST), [18F]FP-R01-MG-F2 (DRUG).
Who is sponsoring clinical trial NCT02683824?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.